Subjective well-being is at least a valuable addition to objective (?) psychopathology, and should become an integral part of shared decision-making. A better consideration of the patients’ perspective can improve therapeutic alliance, medication adherence, and, finally, the long-term prognosis. Selected abbreviations and acronyms PANSS Positive and Negative Syndrome Scale SOHO Neratinib mouse Schizophrenia Outpatient Health Outcomes study SUD substance

use disorder SW subjective well-being SWN Subjective Well-being under Neuroleptic treatment
For the past half-century or so, the US Food and Drug Administration (FDA) has licensed drugs for use in schizophrenia only if they Inhibitors,research,lifescience,medical reduced the positive symptoms of psychosis. This limitation was identified as a bottleneck preventing the identification and development of novel treatments for the problems experienced by schizophrenia patients.1,2 Implicitly, the FDA operated from the assumption that one must treat the entire disorder

with one compound, Inhibitors,research,lifescience,medical rather Inhibitors,research,lifescience,medical than treat specific clinical problems with specific compounds. It has become widely accepted that a cluster of cognitive deficits – which have been long recognized as being important aspects of schizophrenia – are not treated adequately, if at all, by existing antipsychotic treatments.2,3 Furthermore, evidence has accumulated that these cognitive Inhibitors,research,lifescience,medical deficits are largely responsible for the disappointingly poor functional outcome demonstrated by antipsychotic-treated patients with schizophrenia.4 Thus, despite the fact that many antipsychotic treatments have been identified and licensed, the cognitive deficits remain as clinical problems in schizophrenia,

and most patients cannot work. The Inhibitors,research,lifescience,medical MATRICS program MATRICS: moving beyond antipsychotics In response to the identification of the bottleneck limiting the development of treatments specifically directed at the cognitive deficits in schizophrenia, the US National Institute of Mental Health (NIMH) developed the Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS) program. Tolmetin MATRICS set out to develop a broad consensus regarding the nature of the cognitive impairments in schizophrenia and how they might best be assessed and treated.5 The MATRICS approach to the problem is to treat cognitive deficits and psychotic symptoms separately. The NIMH awarded the MATRICS contract to the University of California Los Angeles (UCLA) (Drs Stephen Marder and Michael Green, Co-principal Investigators) in 2002. Over the subsequent 2 years, MATRICS gathered the relevant stakeholders in both industry and academia to achieve a consensus and establish a clear path that would enable the FDA to consider registering compounds intended to treat cognitive deficits in schizophrenia, independently of treating psychosis per se.